CNTB - Connect Biopharma stock rises on positive data from dermatitis mAb

2023-11-21 06:27:03 ET

Connect Biopharma ( NASDAQ: CNTB ) shares jumped 28% premarket on Tuesday after the biopharmaceutical company reported positive long-term data from a trial evaluating its rademikibart drug candidate in patients with moderate-to-severe atopic dermatitis (AD).

Positive topline results were observed in the Stage 2 (maintenance period) of a China pivotal trial evaluating rademikibart's efficacy and safety in AD patients. These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.

In Stage 2, patients that achieved EASI-50 (responders) regardless of initial treatment in the 16-week Stage 1 were randomized to either every two weeks (Q2W) or every four weeks of dosing regimens

Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both Q2W and Q4W doses. Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52.

Additionally, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increase over 36 weeks of treatment in Stage 2.

"We are very pleased with the Stage 2 results of our pivotal China trial, showing that the strong improvements observed in patients at Week 16 in Stage 1 were maintained with both every two weeks and every four weeks dosing regimens," said Zheng Wei, co-founder and CEO of Connect Biopharma.

More on Connect Biopharma

• Connect Biopharma receives Nasdaq notification regarding minimum bid price deficiency
• Seeking Alpha’s Quant Rating on Connect Biopharma
• Historical earnings data for Connect Biopharma
• Financial information for Connect Biopharma

For further details see: